60 studies on IGF-1 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 17 published IGF-1 COA source records from third-party laboratories, covering 10 publicly attributable vendor identities. Across 11 records with positive numeric purity, the arithmetic mean is 99.17%. 0 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 0 positive purity results are below 90%; 0 records report measured amount more than 10% below the label. The latest recorded test date is 2026-03-07. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-03-07. Aggregate calculated: 2026-10-18T04:26:37.976310+00:00. Calculation time is not a laboratory observation date.
Within that total, 6 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Recent source records: #86142 (99.81%) · #20106 (98.134%) · #15360 (98.134%) · #95781 (98.587%) · #23248 (99.456%) · #23216 (99.563%)
Understanding the local pharmacokinetics of IGF-I in muscle tissue is critical for optimizing therapeutic strategies for Type 1 Diabetes Mellitus. If the microdialysis technique proves reliable for measuring interstit…
The continuation of similar monitoring efforts, as seen in the ongoing Increlex® Global Registry (NCT00903110), underscores the importance of continuous post-market surveillance for this patient population.
If the study demonstrates positive results, it could establish recombinant human growth hormone (rhGH) as a critical and effective treatment for short stature in children with chronic kidney disease prior to transplan…
This study is significant because it could elucidate the precise role of IGF-1 in the pathogenesis of vitiligo, specifically its interaction with oxidative stress. Understanding this mechanism could open new avenues f…
Despite its termination, this study highlights the ongoing effort to understand and optimize treatments for Primary IGF-1 Deficiency, a condition causing significant growth failure in children. The intent was to gathe…
While the specific, detailed results from this completed Phase 2 clinical trial (NCT01777542) are not included in the provided record, the study's primary objective was to evaluate the efficacy and safety of recombina…
This Phase 2 trial represents a significant step in exploring targeted treatments for Phelan-McDermid Syndrome, a condition with limited therapeutic options. If IGF-1 proves safe and effective in subsequent studies, i…
The development of a sustained-release human growth hormone (SR-hGH) formulation could significantly improve treatment adherence and quality of life for children with Idiopathic Short Stature (ISS) by reducing injecti…
The successful completion of this Phase 1 trial is a crucial step towards providing a more convenient treatment option for children with Growth Hormone Deficiency. A long-acting growth hormone like somapacitan could s…
If successful, this trial could establish **dietary interventions as a valuable adjunctive strategy for managing acromegaly**, potentially improving hormonal control and patient quality of life beyond current pharmaco…
The termination of this trial highlights the significant challenges in developing and testing combination therapies for complex conditions like IGF-1 deficiency and short stature. While this specific study did not yie…
Sandostatin LAR is a well-established treatment for acromegaly, and this study aimed to refine our understanding of its comprehensive benefits beyond just hormone suppression. Demonstrating clear improvements in metab…
This study is significant because it explores the practical application of lanreotide Autogel 120 mg at extended dosing intervals, potentially offering a more convenient and less burdensome treatment schedule for pati…
The successful completion of this Phase 3 trial is a significant step towards developing an effective treatment for primary IGF-1 deficiency, a condition with limited therapeutic options. rhIGF-1 (mecasermin) holds su…
This pioneering single-patient study represents an early, crucial exploration into a novel therapeutic approach for a complex and rare genetic disease. Targeting low IGF-1 levels in Werner's Syndrome patients with ost…
This research highlights Kisspeptin's potential as a therapeutic agent for mitigating the adverse effects of maternal hypothyroidism on pregnancy outcomes. The restoration of placental mTOR signaling and glucose homeo…
This synthesis of evidence underscores the critical role of growth hormone (GH) in driving breast cancer progression, metastasis, and angiogenesis, moving beyond the traditional focus on steroid hormones. Understandin…
This comprehensive review highlights the critical role of IGF-1 in MASLD pathogenesis, suggesting it's not just a correlative factor but potentially a key player. The most significant implication is that IGF-1 levels …
The establishment of accurate normative ranges for IGF-1, IGFBP-3, and ALS is profoundly important for pediatric endocrinology. These reference values provide clinicians with the necessary tools to differentiate betwe…
This global registry represents a crucial step in understanding the long-term safety and effectiveness of Increlex® for SPIGFD. By collecting data from a large, diverse patient population over many years, it can ident…
**GH's ability to suppress mammary `TPH1` and thereby reduce local serotonin synthesis** adds a mechanistic layer that is entirely separate from the classical GH → IGF-I axis, meaning that stacking GH with LR3 could e…
These findings suggest that **IGF-1 LR3 could be a viable strategy to safely increase both heart muscle and its supporting blood supply before birth**. For potential therapeutic applications aimed at improving congeni…
This research provides a potential mechanistic explanation for the reduced β-cell function seen in overgrown newborns from pregnancies complicated by conditions like diabetes. The finding that elevated IGF-1 can direc…
This Phase 4 study is significant because it investigates a sequential therapy approach for Thyroid Associated Ophthalmopathies (TAO), a debilitating condition often resistant to current treatments. IBI311, as an anti…
This research is critical for understanding the molecular mechanisms behind skin aging and its response to environmental stressors like UVB. If Insulin-Like Growth Factor 1 proves effective in modulating gene expressi…
If GHRH were found to be effective, this research could pave the way for a novel therapeutic strategy to address age-related sleep disturbances, a widespread issue affecting millions. Successfully augmenting the GH-IG…
The intent behind this study highlights a critical challenge in endocrinology: the potential for significant inter-assay variability to compromise the accurate diagnosis and management of Growth Hormone (GH) disorders…
This foundational Phase 1 study is critical because it provides essential data on how Tesamorelin behaves in HIV positive patients, a population with unique metabolic considerations. The successful characterization of…
The withdrawal of this study means a significant opportunity was missed to explore a potential therapeutic avenue for muscle wasting in advanced CKD. Sarcopenia in CKD patients is a major predictor of morbidity and mo…
**Finding GHRP-2 in commercially available nutritional supplements** means athletes and consumers may be unknowingly ingesting a non-approved peptide with systemic GH-releasing activity, creating both unintentional do…
The study demonstrates two distinct and effective pharmacological pathways to combat growth retardation caused by somatotropic axis deficiency. For users of growth hormone secretagogues, this provides evidence that **…
For athletes and regulatory bodies, this research provides a pathway to more effective and reliable anti-doping controls for hGH. The identification of `RAB31` and `FN1` as robust biomarkers could lead to new testing …
This research reveals a novel and critical role for the RECK protein in maintaining the stability and proper function of the GH/IGF-1 axis. The observed discordance between receptor protein levels and their mRNA sugge…
**Systemic GH secretagogue use — including MK-0677 — does not elevate CNS IGF-1 or GH levels**, which has direct implications for researchers and clinicians who hypothesize that peripheral GH/IGF-1 elevation might pro…
**Oral MK-677 produced measurable increases in both bone formation and resorption markers**, suggesting coupled bone remodeling rather than isolated catabolism — a more favorable skeletal profile than pure resorption-…
**Clinicians and advanced users should note the transient nature of leptin elevation** — an effect that normalizes by 8 weeks — which suggests early adaptation in the `leptin` signaling axis and argues against long-te…
**GH secretagogues represent a potentially superior alternative to exogenous GH** for older adults or clinicians pursuing somatotropic support, because they work through the body's own pulse-generation machinery rathe…
**Femoral neck fracture is among the most clinically consequential osteoporotic injuries**, making even a modest site-specific BMD advantage potentially meaningful for fracture prevention — the combination's **+1.7 pe…
This review underscores the critical role of the GH/IGF-1 axis in maintaining bone health and highlights the therapeutic potential of both GH and GHSs for bone disorders. The development of GHSs, which stimulate the b…
**The 84% IGF-1 elevation confirms MK-0677 reliably engages its target even in elderly, post-surgical patients** — a pharmacokinetically important signal for clinicians and researchers designing GH-axis interventions.…
Free, no account — handy when you're working with IGF-1.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account